SARS-CoV-2 serology by mild symptoms of disease

Published: 24-05-2020 Last updated: 09-04-2024

Determination of the sensitivity of diverse SARS-CoV-2 antibodyassays in patients with proven SARS-CoV-2 infection but mild symptoms.

Ethical reviewApproved WMOStatusRecruitment stoppedHealth condition typeViral infectious disordersStudy typeObservational non invasive

Summary

ID

NL-OMON50020

Source

ToetsingOnline

Brief title

SARS-CoV-2 serology

Condition

Viral infectious disorders

Synonym

SARS-CoV-2 infection

Research involving

Human

Sponsors and support

Primary sponsor: Medlon b.v. Medische Diagnostiek

Source(s) of monetary or material Support: Medlon b.v.

Intervention

Keyword: antibody testing, SARS-CoV-2, serology, validation

Outcome measures

Primary outcome

Sensitivity of the diverse assays in a population of patients with mild symptoms.

Secondary outcome

not applicable

Study description

Background summary

The SARS-CoV-2 virus is spread all around the world. The presence of the virus can be demonstrated in nasal swabs by PCR. However antibody testing for this virus is important to prove if a patient has had the disease in the previous period. A lot of commercial assays are nowadays on the market and assaycharacteristics should be determined especially in patients with mild symptoms.

Study objective

Determination of the sensitivity of diverse SARS-CoV-2 antibodyassays in patients with proven SARS-CoV-2 infection but mild symptoms.

Study design

Patients with a positive PCR in their nasal swab who are not hospitalized, are recruited. Blood is drawn by venapuncture. The samples are tested in diverse available antibodyassays.

Study burden and risks

There is no extra risk other than the risk of a venous bloodsampling. The sampling will be done by experienced personell.

Contacts

Public

Medlon b.v. Medische Diagnostiek

Koningsplein 1 Enschede 7500 KA NI

Scientific

Medlon b.v. Medische Diagnostiek

Koningsplein 1 Enschede 7500 KA NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

18 years or older
Abliity to read and understand informed consent
Proven SARS-CoV-2 infection more than three weeks ago.
No hospitalisation for more than three month
No clinical symptoms of active infection at the time of bloodsampling

Exclusion criteria

age of 17 years or younger Unable to read the informed consent

Study design

Design

Study type: Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 15-06-2020

Enrollment: 50

Type: Actual

Ethics review

Approved WMO

Date: 24-05-2020

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL74124.100.20

Study results

Date completed: 09-12-2020

Actual enrolment: 39